The Role of Cancer Stem Cells (CD133+) in Malignant Gliomas
The Role of Cancer Stem Cells (CD133+) in Malignant Gliomas
复制标题
DOI：
10.3727/096368910x532774
复制
发表时间：
2011-01-01
影响因子：
3.3
通讯作者：
Chiu, Shao-Chih
中科院分区：
文献类型：
--
作者：
Cho, Der-Yang;Lin, Shinn-Zong;Chiu, Shao-Chih
恶性胶质瘤，特别是多形性胶质母细胞瘤（GBM）肿瘤，很难用常规方法治疗。虽然大部分肿瘤可以通过手术切除、放疗和化疗去除，但它最终会复发。越来越多的证据表明，肿瘤干细胞（cancer stem cells, CSCs）在肿瘤复发中起重要作用。这些干细胞具有放射抗性和化学抗性。CSCs最常用的肿瘤标志物是CD133。CSC成分的含量与肿瘤的恶性分级密切相关。分离、鉴定和治疗CSCs是治疗恶性胶质瘤的关键。csc相关的血管内皮生长因子（VEGF）促进肿瘤血管生成、肿瘤出血和肿瘤浸润。微rna （miRNA）在CSC基因表达中发挥作用，通过调控肿瘤发生或抑制来影响肿瘤的发生或进展。造血干细胞与正常干细胞的抗原性可能不同。造血干细胞可以逃避t细胞的免疫反应。从CSCs中鉴定新的特异性抗原用于疫苗治疗是免疫治疗的关键。另一方面，放射增敏剂或化学增敏剂的强化治疗可能导致CSCs的减少，导致CSCs易受放疗和化疗的影响。控制信号通路和细胞分化对CSC生长的影响是治疗恶性胶质瘤的又一新希望。虽然干细胞和正常干细胞之间的许多生理行为差异尚不清楚，但我们对这些差异了解得越多，我们就能更好地有效治疗干细胞。
Malignant gliomas, particularly glioblastoma multiforme (GBM) tumors, are very difficult to treat by conventional approaches. Although most of the tumor mass can be removed by surgical resection, radiotherapy, and chemotherapy, it eventually recurs. There is growing evidence that cancer stem cells (CSCs) play an important role in tumor recurrence. These stem cells are radioresistant and chemoresistant. The most commonly used tumor marker for CSCs is CD133. The amount of CSC component is closely correlated with tumor malignancy grading. Isolating, identifying, and treating CSCs as the target is crucial for treating malignant gliomas. CSC-associated vascular endothelial growth factor (VEGF) promotes tumor angiogenesis, tumor hemorrhage, and tumor infiltration. Micro-RNA (miRNA) plays a role in CSC gene expression, which may regulate oncogenesis or suppression to influence tumor development or progression. The antigenesis of CSCs and normal stem cells may be different. The CSCs may escape the T-cell immune response. Identifying a new specific antigen from CSCs for vaccine treatment is a key point for immunotherapy. On the other hand, augmented treatment with radiosensitizer or chemosensitizer may lead to reduction of CSCs and lead to CSCs being vulnerable to radiotherapy and chemotherapy. The control of signaling pathway and cell differentiation to CSC growth is another new hope for treatment of malignant gliomas. Although the many physiological behavioral differences between CSCs and normal stem cells are unclear, the more we know about these differences the better we will be able to treat CSCs effectively.